全文获取类型
收费全文 | 94篇 |
免费 | 5篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 2篇 |
基础医学 | 4篇 |
临床医学 | 14篇 |
内科学 | 22篇 |
特种医学 | 1篇 |
外科学 | 22篇 |
预防医学 | 8篇 |
眼科学 | 6篇 |
药学 | 7篇 |
肿瘤学 | 11篇 |
出版年
2022年 | 2篇 |
2021年 | 1篇 |
2019年 | 2篇 |
2018年 | 2篇 |
2017年 | 1篇 |
2016年 | 3篇 |
2015年 | 2篇 |
2014年 | 10篇 |
2013年 | 5篇 |
2012年 | 9篇 |
2011年 | 6篇 |
2010年 | 4篇 |
2009年 | 3篇 |
2008年 | 6篇 |
2007年 | 9篇 |
2006年 | 10篇 |
2005年 | 5篇 |
2004年 | 6篇 |
2003年 | 3篇 |
2002年 | 3篇 |
2000年 | 1篇 |
1995年 | 1篇 |
1991年 | 1篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1979年 | 1篇 |
排序方式: 共有99条查询结果,搜索用时 31 毫秒
21.
22.
23.
24.
Objective Before undergoing sacral nerve stimulation (SNS) for faecal incontinence (FI), patients are investigated with morphologic, dynamic and electrophysiologic tests. The purpose of our study was to evaluate their value in the selection of patients who may benefit most from neuromodulation. Method If temporary stimulation resulted in a good objective response, a permanent neuromodulator was implanted. Patients were reviewed at 3 months and then at 6 monthly intervals. Asked by telephone, patient’s satisfaction was described as good, satisfactory or poor. Results Forty‐five consecutive patients (41 females, median age 59 years) with FI (Wexner 16.1 ± 2.9) underwent SNS. Temporary stimulation was successful in 32 (71)% patients. At a median follow‐up of 33 months, the neuromodulator remained in place in 25 (55%) patients, two do whom switched it off, leaving 23 (51%) with a functioning neuromodulator. There was no statistically significant difference between the characteristics (including manometry, ultrasound and electrophysiology) of patients undergoing implantation (n = 32) or not (n = 13) and those with or without a functioning stimulator (n = 23: n = 13). In the 23 patients with a functioning stimulator the result was good in 12, satisfactory in five and poor in six. There was no statistically significant difference in the patient characteristics between those with a good result (n = 12) and the remainder (n = 32). Conclusion The findings suggest that investigation for FI does not facilitate patient selection for SNS and cannot be used to predict outcome. 相似文献
25.
Alvaro P. C. Lupinacci Jorge I. Calzada Mohammad Rafieetery Steve Charles Peter A. Netland 《Advances in therapy》2009,26(2):208-216
Introduction The purpose of this study was to evaluate the clinical outcomes of patients with anterior segment neovascularization treated
with or without intravitreal bevacizumab.
Methods This was a retrospective, comparative case series of 60 patients with anterior segment neovascularization: 30 consecutive
patients treated with intravitreal bevacizumab and 30 age-, gender-, and race-matched controls treated without bevacizumab.
Results The mean follow-up time was 9.1±6.3 months in the bevacizumab group and 8.6±6.2 months in the control group (P=0.769). At baseline, no significant difference was observed in initial visual acuity, intraocular pressure, gonioscopy, and
iris or angle neovascularization (P=0.179, 0.432, 0.065, and 0.966, respectively). At the final examination, no significant difference was observed in mean intraocular
pressure (P=0.464), mean number of glaucoma medications (P=1.00), or presence of anterior segment neovascularization (P=0.699). Final visual acuity better than 20/60 was achieved in six patients in the bevacizumab group and none in the control
group (P=0.013). Comparison of linear regressions of baseline and final visual acuity (LogMAR) showed a significant difference between
the two groups (P=0.040). In the bevacizumab group, 18 patients required glaucoma surgery, whereas 30 patients in the control group required
surgery (P<0.001), usually with a glaucoma drainage implant. Both bevacizumab and control patients who presented with closed angles
required glaucoma surgery (P=1.000).
Conclusions Treatment of anterior segment neovascularization with intravitreal bevacizumab significantly improves visual outcomes and
significantly decreases the need for glaucoma surgery. In patients with closed anterior chamber angle, addition of bevacizumab
treatment does not reduce the need for glaucoma surgery. 相似文献
26.
We would like to estimate the parameters of a dose-response function with the greatest precision as possible. For a two-parameter model, this is equivalent to minimizing the area of the confidence ellipsoid, i.e., a D-optimal design. Previous work on this particular model has included minimal designs. These designs are unable to determine lack of fit. We introduce a distinct dose level to the design to be able to estimate the lack of fit. The minimal and new designs will be compared, and the sample size needed to achieve adequate power for the lack-of-fit test will be derived. 相似文献
27.
Li SX Pequignot E Panebianco D Lupinacci P Majumdar A Rosen L Ahmed T Royalty JE Rushmore TH Murphy MG Petty KJ 《Journal of clinical pharmacology》2006,46(7):792-801
To prevent chemotherapy-induced nausea and vomiting, aprepitant is given with a corticosteroid and a 5-hydroxytryptamine type 3 antagonist, such as dolasetron. Dolasetron is converted to the active metabolite hydrodolasetron, which is cleared largely via CYP2D6. The authors determined whether aprepitant, a moderate CYP3A4 inhibitor, alters hydrodolasetron pharmacokinetics in CYP2D6 poor and extensive metabolizers. Six CYP2D6 poor and 6 extensive metabolizers were randomized in an open-label, crossover fashion to treatment A (dolasetron 100 mg on day 1) and treatment B (dolasetron 100 mg plus aprepitant 125 mg on day 1, aprepitant 80 mg on days 2-3). For hydrodolasetron area under the concentration-versus-time curve (AUC0-infinity) and peak plasma concentration (Cmax), geometric mean ratios (B/A) and 90% confidence intervals (CIs) fell below the predefined limit (2.0) for clinical significance (AUC0-infinity, 1.09 [90% CI, 1.01-1.18], Cmax, 1.08 [90% CI, 0.94-1.24]). Aprepitant did not affect the pharmacokinetics of hydrodolasetron, regardless of CYP2D6 metabolizer type, and was generally well tolerated when coadministered with dolasetron in volunteers. 相似文献
28.
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18 总被引:16,自引:0,他引:16
Villa LL Ault KA Giuliano AR Costa RL Petta CA Andrade RP Brown DR Ferenczy A Harper DM Koutsky LA Kurman RJ Lehtinen M Malm C Olsson SE Ronnett BM Skjeldestad FE Steinwall M Stoler MH Wheeler CM Taddeo FJ Yu J Lupinacci L Railkar R Marchese R Esser MT Bryan J Jansen KU Sings HL Tamms GM Saah AJ Barr E 《Vaccine》2006,24(27-28):5571-5583
Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naïve and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were ∼12- to 26-fold higher than those observed in baseline-naïve women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported. 相似文献
29.
M. J. DiNubile K. M. Strohmaier R. J. Lupinacci A. R. Meibohm C. A. Sable N. A. Kartsonis 《European journal of clinical microbiology & infectious diseases》2008,27(8):663-670
Invasive fungal infections (IFIs) are serious complications in elderly adults. Caspofungin may provide a useful therapeutic option for elderly patients with or at high risk for IFIs. We retrospectively compared efficacy and safety outcomes in elderly (>/=65 years of age) and non-elderly patients in three clinical trials of caspofungin: a double-blind, randomized trial versus amphotericin B for documented invasive candidiasis (IC); an open-label, non-comparative study of definite or probable invasive aspergillosis (IA); and a double-blind, randomized trial versus liposomal amphotericin B as empirical therapy (ET) in febrile neutropenic patients. A total of 159 elderly patients with a median age of 71 years (range, 65-84) received caspofungin in these studies. The median duration of caspofungin therapy was 12 days for IC and ET, and 28 days for IA. Point estimates for the favorable response rates to caspofungin were numerically higher in elderly versus non-elderly patients with IC (83% vs. 68%) or IA (64% vs. 44%) and were similar in patients receiving ET (36% vs. 34%). Adverse events related to caspofungin occurred in generally similar proportions of elderly versus non-elderly patients with IC (clinical, 33% vs. 27%; laboratory, 17% vs. 29%), with IA (clinical, 7% vs. 13%; laboratory, 13% vs. 14%), or receiving ET (clinical, 47% vs. 47%; laboratory, 24% vs. 22%). Nephrotoxicity and infusion-related toxicity developed in comparable proportions of elderly and non-elderly caspofungin recipients in all three studies. In this post-hoc analysis, caspofungin appeared to be as efficacious and well tolerated in elderly patients as in non-elderly patients. 相似文献
30.
Stefano Mazza Nicole Piazza O. Sed Francesco Simone Conforti Alberto Fascì Alessandro Rimondi Beatrice Marinoni Valentina Casini Chiara Ricci Francesca Munari Lorena Pirola Pietro Invernizzi Carlo Girelli Guido Lupinacci Luca Pastorelli Flaminia Cavallaro Luca Ferraris Alice Colucci Arnaldo Amato Gian Eugenio Tontini Maurizio Vecchi Gionata Fiorino Flavio Caprioli 《CTS Clinical and Translational Science》2022,15(1):172
Data regarding double switching from originator infliximab (IFX) to IFX biosimilars in inflammatory bowel diseases (IBDs) are lacking. The purpose of this study was to evaluate the safety and efficacy of switching from originator IFX to CT‐P13 and subsequently to SB2 (double switch) in patients with IBD. Patients undergoing IFX‐double switch in eight Centers in Lombardy (Italy) from November 2018 to May 2019 were retrospectively analyzed. The IFX discontinuation rate, incidence and type of adverse events (AEs), and clinical remission rate were recorded. A comparison with a control group of patients with IBD single‐switched from originator IFX to CT‐P13 was performed, before and after an inverse probability of treatment weighting (IPTW)‐based propensity score analysis. Fifty‐two double‐switched patients with IBD were enrolled. The 24‐ and 52‐week proportions of patients continuing on IFX therapy following the second switch (CTP13 → SB2) were 98% (95% confidence interval [CI] 94%–100%) and 90% (95% CI 81%–99%), respectively. Four patients experienced a total of five AEs, all graded 1–3 according to Common Terminology Criteria for Adverse Events (CTCAE). No infusion reactions were observed. The 24‐week and follow‐up end clinical remission rates following the second switch were 94% and 88%, respectively. No differences were observed in the safety and efficacy outcomes by comparing the double‐switch group with a single‐switch group of 66 patients with IBD; all these results were confirmed by IPTW‐adjusted analysis. The study suggests both the safety and efficacy of the double switch from originator IFX to CT‐P13 and SB2 in patients with IBD is maintained. This strategy may be associated with potential cost implications. Study Highlights
- WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
- WHAT QUESTION DID THIS STUDY ADDRESS?
- WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
- HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?